128 related articles for article (PubMed ID: 12171898)
1. Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts.
Salcedo R; Martins-Green M; Gertz B; Oppenheim JJ; Murphy WJ
Clin Cancer Res; 2002 Aug; 8(8):2655-65. PubMed ID: 12171898
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
3. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
6. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis.
Kuniyasu H; Ohmori H; Sasaki T; Sasahira T; Yoshida K; Kitadai Y; Fidler IJ
Clin Cancer Res; 2003 Oct; 9(13):4802-10. PubMed ID: 14581351
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
[TBL] [Abstract][Full Text] [Related]
10. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
11. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
13. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
14. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
15. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
16. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
17. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
18. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
Fan Z; Baselga J; Masui H; Mendelsohn J
Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
